Why Do Uterine Polyps Bleed?

Uterine polyps bleed primarily because they are packed with abnormally fragile blood vessels. The tissue that makes up a polyp grows its own blood supply, but those vessels tend to have unusually thin walls, making them prone to rupture with even minor mechanical stress from uterine contractions, intercourse, or the normal hormonal cycling of the menstrual period. Research comparing polyps that cause abnormal bleeding to those that don’t has found that the vessel walls in bleeding polyps are roughly a third thinner than in their silent counterparts. That fragility, combined with hormonal imbalances, localized inflammation, and the polyp’s exposed position jutting into the uterine cavity, creates a structure that is almost engineered to leak blood at inconvenient times.

Thin-Walled Vessels at the Core of the Problem

A polyp is essentially an overgrowth of the uterine lining that forms a small, finger-like projection into the uterine cavity. Like any living tissue, it needs a blood supply to survive, and blood vessels grow into the polyp as it develops. The trouble is that these vessels don’t form the way normal endometrial vessels do. They tend to be dilated and structurally weak, with walls far thinner than you’d find in healthy uterine tissue.

A morphometric study that directly measured vessel-wall thickness in polyps found that among patients with abnormal bleeding, the average wall thickness was about 16.5 micrometers, compared to roughly 24.8 micrometers in patients whose polyps were not causing bleeding. When the researchers grouped vessels by wall thickness, about 60 percent of vessels in bleeding polyps had walls thinner than 20 micrometers, while only 13 percent had thick walls above 30 micrometers.¹ Those numbers help explain something clinicians have long observed: not every polyp bleeds, but the ones that do almost always have structurally compromised vessels. A polyp sitting inside the uterine cavity gets jostled with every contraction, and if its blood supply is built from tissue-paper-thin tubes, even routine physical forces can cause them to break open.

Abnormal Blood Vessel Growth Makes Things Worse

The fragile vessels inside polyps aren’t just an accident of tissue growth. The polyp tissue itself actively drives the formation of new, poorly constructed blood vessels through a process called angiogenesis. One of the key signals involved is vascular endothelial growth factor, or VEGF, a protein that tells the body to build new blood vessels. Polyp tissue produces significantly more VEGF than the normal endometrial tissue right next to it.

A study comparing VEGF levels in polyps versus adjacent normal endometrium found that the protein was expressed at significantly higher levels in both the glandular and stromal cells of the polyp. The difference was especially pronounced during the proliferative phase of the menstrual cycle, when estrogen is high and the lining is actively growing.² This matters because VEGF doesn’t just build more vessels; it builds them quickly and somewhat haphazardly. Vessels formed under strong VEGF signaling tend to be leaky and structurally immature, which circles back to the thin-walled vessel problem. The polyp is essentially flooding its own tissue with “build more blood vessels” signals, but those vessels are rushed into service and poorly reinforced.

Alongside VEGF, a growth factor called TGF-β1 was also elevated in polyp tissue, suggesting that the growth environment inside a polyp favors tissue remodeling in ways that don’t produce sturdy structures.² The combination of excessive vessel formation and structurally weak results is a recipe for bleeding.

The Estrogen Connection

Estrogen plays a central role in both why polyps form and why they bleed. The endometrial lining is highly responsive to estrogen, and polyps appear to develop in environments where estrogen signaling is unchecked by the balancing effects of progesterone. This hormonal imbalance doesn’t just create the polyp; it maintains the conditions that keep the polyp growing, vascularized, and prone to bleeding.

Estrogen stimulates growth of the endometrial lining and its blood supply. In normal menstrual cycling, progesterone counterbalances this effect during the second half of the cycle, stabilizing the tissue and the vessels within it. In polyps, there is evidence that the tissue overexpresses estrogen receptors and underexpresses progesterone receptors, meaning the polyp is disproportionately responsive to estrogen’s “grow” signal and relatively deaf to progesterone’s “stabilize” signal.³ The practical result is that the polyp’s blood vessels keep proliferating without the structural reinforcement that progesterone normally provides. This is one reason polyps bleed at different times than normal menstruation, and why they can cause spotting between periods or prolonged, heavier-than-usual flow.

This hormonal mechanism also helps explain why polyps are more common in certain populations: people approaching menopause (when cycles become more erratic and estrogen often goes unopposed for longer stretches), those with obesity (fat tissue produces extra estrogen), and those on hormone replacement therapy that supplies estrogen without adequate progesterone.

Inflammation as a Trigger and Perpetuator

Beyond the structural and hormonal explanations, a growing body of evidence points to chronic low-grade inflammation as a factor that both promotes polyp formation and worsens bleeding. The uterine lining isn’t just a passive surface; it’s immunologically active, and when that local immune environment tips toward chronic inflammation, it can alter the tissue in ways that favor polyp growth.

One piece of evidence comes from research on platelet activation. A study of patients with endometrial polyps found that their mean platelet volume (a marker of platelet activation and vascular inflammation) was significantly higher than in controls. Elevated platelet activity is associated with inflammatory and clot-related conditions throughout the body, and in the uterus, it suggests that inflammatory signaling contributes to the abnormal tissue remodeling seen in polyps.⁴ Inflammation makes blood vessels more permeable and promotes the kind of chaotic tissue growth that weakens vessel walls.

A separate line of evidence ties polyps to chronic endometritis, a condition where the uterine lining harbors persistent, low-level inflammation marked by the presence of specific immune cells called plasma cells. A study comparing patients with and without polyps found that chronic endometritis was present in about 45 percent of polyp patients, compared to roughly 17 percent in controls.⁵ This suggests that a chronically inflamed uterine lining may be a breeding ground for polyps, and that the same inflammatory environment keeps the tissue fragile and bleed-prone. The inflammation doesn’t just sit in the background; it actively participates in breaking down normal tissue structure and promoting abnormal vessel formation.

Why Not Every Polyp Bleeds

One of the more puzzling aspects of uterine polyps is that many of them cause no symptoms at all. Estimates suggest that a substantial proportion of polyps are discovered incidentally during imaging done for other reasons. The difference between a “silent” polyp and a bleeding one comes down to a combination of factors rather than one single trait.

Size matters, though not in a perfectly linear way. Larger polyps have more surface area exposed to the uterine cavity and more vessels that can rupture. Location within the uterus plays a role too: a polyp near the cervix or one that protrudes through the cervical opening is more likely to be subjected to mechanical friction during intercourse or physical activity. And as the vessel-wall data described earlier shows, the internal vascular architecture of the polyp itself is the most direct predictor. A small polyp with exceptionally thin-walled vessels may bleed persistently, while a larger one with more robust vasculature might never announce its presence.

Hormonal status also affects whether a polyp bleeds. In premenopausal people, the cyclical rise and fall of estrogen and progesterone means the polyp is repeatedly stimulated and then partially destabilized, a cycle that makes bleeding more likely around menstruation or mid-cycle. After menopause, estrogen levels drop, and polyps in that setting may remain dormant for long periods. When a postmenopausal polyp does bleed, it deserves prompt attention because the differential diagnosis shifts in a direction that includes more concerning possibilities.

When Bleeding Polyps Warrant Closer Scrutiny

Most uterine polyps are benign. But bleeding from a polyp, especially in certain clinical contexts, raises the question of whether the tissue harbors precancerous or cancerous changes. This is where the symptom of bleeding becomes diagnostically important, not just a nuisance.

A large systematic review and meta-analysis examining malignancy risk in uterine polyps found that symptomatic polyps (those causing abnormal bleeding) carried a malignancy rate of about 5 percent, compared to roughly 2 percent in asymptomatic ones.⁶ That gap is statistically significant and clinically meaningful. A 12-year institutional study found that in addition to bleeding, patient age, menopausal status, and hypertension were all linked to the likelihood of finding premalignant or malignant features in a polyp.⁷

The postmenopausal context is especially important. In women with postmenopausal bleeding, polyps are among the most common structural findings, and the risk of a focal malignancy within such a polyp has been estimated at up to 6 percent.⁸ This is why guidelines generally recommend removing polyps that cause bleeding, rather than watching them, particularly in postmenopausal patients or those with additional risk factors like obesity and hypertension. The bleeding itself doesn’t mean cancer is present, but it moves the probability just enough that removing and examining the tissue under a microscope becomes the prudent course.

Tamoxifen and a Different Kind of Polyp

Tamoxifen, a medication widely used in the treatment of estrogen receptor-positive breast cancer, deserves its own discussion because it produces polyps that are structurally and behaviorally distinct from the typical kind. Tamoxifen acts as an estrogen blocker in breast tissue but has estrogen-like effects on the uterine lining, creating a paradox that leads to a higher rate of polyp formation and a different risk profile.

The incidence of polyps in tamoxifen-treated patients ranges from about 8 to 36 percent, compared to up to 10 percent in untreated populations. These polyps also tend to be dramatically larger, averaging around 5 centimeters in diameter compared to 0.5 to 3 centimeters in the general population. Under the microscope, tamoxifen-related polyps look different too, with a mix of proliferative activity and unusual tissue differentiation patterns.⁹

What makes tamoxifen-related polyps particularly relevant to the bleeding question is that their aberrant tissue structure and larger size create more surface area with more abnormal vessels, increasing the probability of bleeding. The malignant transformation rate in tamoxifen-related polyps has been reported at 3 to 10.7 percent, a significant jump from the roughly 0.5 percent rate seen in the general population.⁹ For anyone on tamoxifen who develops uterine bleeding, the threshold for investigation and removal should be low. The medication is life-saving for breast cancer, but its uterine effects require ongoing monitoring.

What Happens After Removal

The standard treatment for a symptomatic uterine polyp is hysteroscopic polypectomy, a procedure where a small camera is inserted through the cervix and the polyp is either cut away or suctioned out. The procedure is minimally invasive and usually done as an outpatient surgery. Once the polyp is removed, bleeding typically resolves because the fragile, abnormal vessels are gone along with the tissue they supplied.

Whether bleeding stays gone is a different question. Polyps can recur, and when they do, bleeding often comes back with them. A long-term study comparing two common removal techniques, a tissue removal system and bipolar resection, found that about a quarter to 40 percent of patients eventually experienced a recurrence of abnormal bleeding, though the average time to recurrence was roughly eight to nine years in both groups.¹⁰ There was no meaningful difference between the two techniques in terms of symptom relief or polyp recurrence, which suggests that the underlying predisposition to polyp formation, rather than the surgical method, drives recurrence.

This makes sense when you consider the mechanisms involved. Removing a polyp addresses the immediate structure causing bleeding, but it doesn’t change the hormonal environment, the inflammatory milieu, or the VEGF signaling tendencies of the endometrial tissue. If the conditions that encouraged the first polyp to grow are still present, new polyps can form over time. For people with recurrent polyps and ongoing symptoms, clinicians may discuss hormonal management with a progestin-containing intrauterine device, which delivers progesterone directly to the uterine lining and counteracts the estrogen-driven growth that contributes to polyp development.

The Microbiome Angle

One of the more recent and genuinely surprising areas of research on uterine polyps involves the endometrial microbiome. The uterus was once considered a sterile environment, but that assumption has been upended in the last decade. The uterine cavity hosts its own microbial community, and alterations in that community appear to be linked to polyp formation.

Research using gene sequencing analysis to profile the bacteria present in the uterine lining has found that patients with endometrial polyps have a different microbial composition than healthy controls. The connection to chronic endometritis described earlier fits neatly here: bacterial colonization can trigger persistent low-level inflammation, which in turn promotes the tissue changes that lead to polyp growth and fragile vasculature.⁵ This doesn’t mean an infection “causes” polyps in any straightforward way, but it does suggest that the health of the uterine microbial environment is one more variable in the equation. Whether targeting the microbiome with antibiotics or probiotics could prevent polyp formation or reduce bleeding remains an open question, and the evidence is far too early to guide clinical practice. But it represents a shift in how researchers think about why certain people develop polyps repeatedly while others never do.